

# Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor-positive advanced breast cancer: updated results in treatment-naïve patients

Hope S. Rugo,<sup>1\*</sup> Robert Wesolowski,<sup>2\*</sup> Erica M. Stringer-Reasor,<sup>3</sup> Hyo Han,<sup>4</sup> Jennifer M. Specht,<sup>5</sup> E. Claire Dees,<sup>6</sup> Peter Kabos,<sup>7</sup> Ulka Vaishampayan,<sup>8</sup> Seth A. Wander,<sup>9</sup> Janice Lu,<sup>10</sup> Keerthi Gogineni,<sup>11</sup> Alexander Spira,<sup>12</sup> Anne F. Schott,<sup>13</sup> Maysa Abu-Khalaf,<sup>14</sup> Sarah C. Mutka,<sup>15</sup> Samuel Suzuki,<sup>15</sup> Igor Gorbachevsky,<sup>15</sup> Rachel M. Layman<sup>16\*</sup>

<sup>1</sup>University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA; <sup>2</sup>The Ohio State University Comprehensive Cancer Center, Columbus, OH; <sup>3</sup>Division of Hematology Oncology, Department of Medicine, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL; <sup>4</sup>Moffitt Cancer Center, Tampa, FL; <sup>5</sup>Fred Hutch Cancer Center, University of Washington, Seattle, WA; <sup>6</sup>University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; <sup>7</sup>University of Colorado Hospital, Aurora, CO; <sup>8</sup>Karmanos Cancer Institute, Detroit, MI (at time of study conduct); <sup>9</sup>Massachusetts General Hospital, Harvard Medical School, Boston, MA; <sup>10</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; <sup>11</sup>Emory University Hospital, Atlanta, GA; <sup>12</sup>Virginia Cancer Specialists Research Institute, Fairfax, VA; <sup>13</sup>University of Michigan Rogel Cancer Center, Ann Arbor, MI; <sup>14</sup>Sidney Kimmel Cancer Center at Jefferson Health, Philadelphia, PA; <sup>15</sup>Celcuity, Minneapolis, MN; <sup>16</sup>The University of Texas MD Anderson Cancer Center, Houston, TX

\*These authors contributed equally to this work

204P

Presented at the  
ESMO Breast Annual Congress  
May 11–13, 2023  
Berlin, Germany

## BACKGROUND

It is hypothesized that the addition of a pan-PI3K/mTOR inhibitor after progression on a CDK4/6 inhibitor and endocrine therapy (ET) in estrogen receptor-positive (ER+), HER2-negative advanced breast cancer (ABC) can:

- Potentially restore sensitivity to a CDK4/6 inhibitor; and
- Prevent adaptive activation of the PI3K/mTOR pathway.<sup>1-5</sup>
- To evaluate this hypothesis, a Phase Ib study combining gedatolisib, a dual inhibitor of PI3K/mTOR; palbociclib, a CDK4/6 inhibitor; and endocrine therapy (letrozole or fulvestrant) to treat women with ER+/HER2- ABC was conducted.
- Manageable toxicity and preliminary antitumor activity were observed in 35 patients enrolled in the dose escalation portion of the study<sup>6</sup> and 103 patients enrolled in the expansion portion of the study.<sup>7</sup>
- In this subgroup analysis, we report updated efficacy and safety data in treatment-naïve patients from Escalation Arm A and Expansion Arm A with a June 29, 2022, database lock. Median progression-free survival (mPFS) and Duration of Response (DOR) are updated as of March 16, 2023.

## B2151009 OVERALL STUDY DESIGN

- Patients with ER+/HER2- ABC were treated in two different Arms as shown. Pre-/peri-menopausal women received ovarian suppression therapy.
- 11 treatment-naïve patients (Escalation Arm A) and 30 treatment-naïve patients (Expansion Arm A) were pooled for the sub-group analysis.
- Treatment regimen: gedatolisib 180 mg IV weekly; palbociclib 125 mg PO daily for 21 days followed by seven days off; letrozole 2.5 mg PO daily.
- Tumor assessment was performed at baseline and every 8 weeks until disease progression or the start of a new anti-cancer therapy. Twelve months after enrollment was completed, the protocol was amended to allow tumor assessments every 12–16 weeks. All patients had tumors assessed every eight weeks for at least the first 18 months from their start of therapy.
- Endpoints: Primary - objective response assessed by the investigator; Secondary - safety, duration of response (DOR), and PFS.

Table 1: Baseline Characteristics (Full Analysis Set)

| Parameter                                                        | Escalation Arm A (n = 11) | Expansion Arm A (N = 30) | Total Treatment-Naïve (n = 41) |
|------------------------------------------------------------------|---------------------------|--------------------------|--------------------------------|
| <b>Age</b>                                                       |                           |                          |                                |
| Median years (range)                                             | 50.0 (37.0–74.0)          | 54.5 (28.0–78.0)         | 54.0 (28.0–78.0)               |
| <b>Tumor, Node, Metastasis (TNM) Stage, n (%)</b>                |                           |                          |                                |
| Stage III                                                        | 1 (9.1)                   | 0 (0.0)                  | 1 (2.4)                        |
| Stage IV                                                         | 10 (90.9)                 | 29 (96.7)                | 39 (95.1)                      |
| Stage unknown                                                    | 0 (0.0)                   | 1 (3.3)                  | 1 (2.4)                        |
| <b>Number of Prior Therapies - Advanced Breast Cancer, n (%)</b> |                           |                          |                                |
| 0                                                                | 11 (100.0)                | 30 (100.0)               | 41 (100.0)                     |
| <b>Measurable Baseline Disease, n (%)</b>                        |                           |                          |                                |
| Yes                                                              | 8 (72.7)                  | 30 (100)                 | 38 (92.7)                      |
| No                                                               | 3 (27.3)                  | 0                        | 3 (7.3)                        |
| <b>Prior Adjuvant Endocrine Therapy, n (%)</b>                   |                           |                          |                                |
| Yes                                                              | 2 (18.2)                  | 16 (53.3)                | 18 (43.9)                      |
| No                                                               | 9 (81.8)                  | 14 (46.7)                | 23 (56.1)                      |

<sup>1</sup>PIK3CA status confirmed by liquid biopsy using a central lab.

## SAFETY

Table 2: Treatment Related and Emergent Adverse Events (≥ 20% of Subjects, by SOC and Preferred Term)

| Adverse Event                                               | Treatment-Naïve (N = 41) |           |           |           |
|-------------------------------------------------------------|--------------------------|-----------|-----------|-----------|
|                                                             | Grade 1 %                | Grade 2 % | Grade 3 % | Grade 4 % |
| <b>Gastrointestinal disorders</b>                           |                          |           |           |           |
| Stomatitis <sup>1</sup>                                     | 9 (22.0)                 | 13 (31.7) | 12 (29.3) | 0         |
| Nausea                                                      | 15 (36.6)                | 16 (39.0) | 1 (2.4)   | 0         |
| Diarrhoea                                                   | 12 (29.3)                | 5 (12.2)  | 1 (2.4)   | 0         |
| Vomiting                                                    | 13 (31.7)                | 5 (12.2)  | 0         | 0         |
| Constipation                                                | 11 (26.8)                | 2 (4.9)   | 0         | 0         |
| Dry mouth                                                   | 10 (24.4)                | 0         | 0         | 0         |
| <b>Blood and lymphatic system disorders</b>                 |                          |           |           |           |
| Neutropenia/Neutrophil count decreased <sup>2,3</sup>       | 0                        | 7 (17.1)  | 21 (51.2) | 4 (9.8)   |
| Anaemia                                                     | 4 (9.8)                  | 9 (22.0)  | 4 (9.8)   | 0         |
| <b>Skin and subcutaneous tissue disorders</b>               |                          |           |           |           |
| Rash <sup>2,4</sup>                                         | 11 (26.8)                | 6 (14.6)  | 15 (36.6) | 0         |
| Pruritus                                                    | 8 (19.5)                 | 3 (7.3)   | 4 (9.8)   | 0         |
| <b>General disorders and administration site conditions</b> |                          |           |           |           |
| Fatigue                                                     | 10 (24.4)                | 12 (29.3) | 4 (9.8)   | 0         |
| <b>Nervous system disorders</b>                             |                          |           |           |           |
| Dysgeusia                                                   | 19 (46.3)                | 2 (4.9)   | 0         | 0         |
| Headache                                                    | 6 (14.6)                 | 5 (12.2)  | 0         | 0         |
| <b>Respiratory, thoracic and mediastinal disorders</b>      |                          |           |           |           |
| Epistaxis                                                   | 11 (26.8)                | 0         | 0         | 0         |
| <b>Investigations</b>                                       |                          |           |           |           |
| White blood cell count decreased                            | 1 (2.4)                  | 7 (17.1)  | 5 (12.2)  | 0         |
| Alanine aminotransferase increased                          | 6 (14.6)                 | 1 (2.4)   | 3 (7.3)   | 0         |
| Aspartate aminotransferase increased                        | 7 (17.1)                 | 2 (4.9)   | 0         | 0         |
| Lymphocyte count decreased                                  | 1 (2.4)                  | 4 (9.8)   | 4 (9.8)   | 0         |
| <b>Musculoskeletal and connective tissue disorders</b>      |                          |           |           |           |
| Arthralgia                                                  | 7 (17.1)                 | 2 (4.9)   | 0         | 0         |
| <b>Metabolism and nutrition disorders</b>                   |                          |           |           |           |
| Hyperglycaemia                                              | 6 (14.6)                 | 4 (9.8)   | 2 (4.9)   | 0         |
| Decreased appetite                                          | 7 (17.1)                 | 2 (4.9)   | 0         | 0         |
| <b>Vascular disorders</b>                                   |                          |           |           |           |
| Hot flush                                                   | 11 (26.8)                | 0         | 0         | 0         |
| <b>Injury, poisoning and procedural complications</b>       |                          |           |           |           |
| Infusion related reaction                                   | 5 (12.2)                 | 6 (14.6)  | 0         | 0         |

There were no Grade 5 treatment related TAEs.

<sup>1</sup>Majority of the pts in this subgroup did not receive prophylactic treatment for stomatitis; <sup>2</sup>Number of patients with at least one of the terms. If a patient experienced multiple terms, it will be counted once for the highest grade; <sup>3</sup>Neutropenia and neutrophil count decrease were reported interchangeably for many patients. In this table, neutropenia (SOC-blood and lymphatic system disorders) and neutrophil count decreased (SOC-investigations) were combined; <sup>4</sup>Rash, rash maculo-papular, rash pruritic, rash pustular, rash papular, rash erythematous, or rash vesicular.

Table 3: Patient Treatment Discontinuation (Full Analysis Set)

|                                                   |  | Total Treatment-Naïve Patients (n = 41) |  |
|---------------------------------------------------|--|-----------------------------------------|--|
| <b>Patients Who Discontinued Treatment, n (%)</b> |  |                                         |  |
| <b>Reasons other than AEs</b>                     |  | 36 (87.8)                               |  |
| Progression or relapse                            |  | 15 (36.6)                               |  |
| Study terminated by sponsor <sup>1</sup>          |  | 9 (22.0)                                |  |
| Other <sup>2</sup>                                |  | 12 (29.3)                               |  |
| <b>Adverse events<sup>3</sup></b>                 |  |                                         |  |
| Treatment related                                 |  | 4 (9.8)                                 |  |
| Unknown                                           |  | 1 (2.4)                                 |  |

<sup>1</sup>After study termination, 9 patients in this subgroup rolled over to an expanded access protocol (EAP) and continued treatment. As of March 16, 2023, 5 of these patients remain enrolled in the EAP; <sup>2</sup>Other includes: withdrawal by subject, lost to follow up, global deterioration, PI decision, new diagnosis-renal cell carcinoma; <sup>3</sup>Treatment related AEs: stomatitis, psoriasis, rash maculo-papular, fatigue (n=1 each).

## EFFICACY

Table 4: Efficacy Summary – Treatment-Naïve Population (1L)


|                                                                        | Escalation Arm A | Expansion Arm A   | Total Treatment-Naïve |
|------------------------------------------------------------------------|------------------|-------------------|-----------------------|
| <b>Responses (Evaluable and Measurable Disease),<sup>1</sup> n (%)</b> | <b>n = 7</b>     | <b>n = 26</b>     | <b>n = 33</b>         |
| CR                                                                     | 0                | 1 (3.8)           | 1 (3.0)               |
| PR                                                                     | 4 (57.1)         | 21 (80.8)         | 25 (75.8)             |
| SD                                                                     | 3 (42.9)         | 3 (11.5)          | 6 (18.2)              |
| Unconfirmed PR                                                         | 0                | 0                 | 0                     |
| Durable SD (≥ 24 weeks)                                                | 1 (14.3)         | 2 (7.7)           | 3 (9.1)               |
| PD                                                                     | 0                | 1 (3.8)           | 1 (3.0)               |
| ORR <sup>1</sup>                                                       | 4 (57.1)         | 22 (84.6)         | 26 (78.8)             |
| Median DOR, mos (95% CI) <sup>2</sup>                                  | 39.7 (30.5, NR)  | 46.9 (11.3, NR)   | 46.9 (24.6, 49.5)     |
| <b>Progression-Free Survival (Full Analysis Set)</b>                   |                  |                   |                       |
| Median PFS, mos (95% CI)                                               | 45.8 (32.3, NR)  | 48.6 (11.6, NR)   | 48.6 (30.4, NR)       |
| Median follow-up, <sup>3</sup> mos, range                              | 18.2 (1.5, NR)   | 37.8 (12.9, 51.6) | 37.8 (14.9, 51.6)     |

The 2 arms were not randomized.

<sup>1</sup>Subjects with measurable disease in response evaluable analysis set per RECIST v1.1; <sup>2</sup>Confirmed responders in the full analysis set; <sup>3</sup>Median follow-up for PFS is per reverse Kaplan-Meier method including two censored patients with a short follow up time.

CR, complete response; DOR, duration of response; mos, months; NR, not reached; ORR, objective response rate; PD, progressive disease; PFS, progression free survival; PR, partial response; SD, stable disease.

Figure 1: Duration of Response for Confirmed Responders in Treatment-Naïve Subgroup (Full Analysis Set)



Subjects at Risk:

Total 26 25 23 22 18 17 16 16 15 12 10 7 5 5 5 5 2 1 1 1 1 0

Note: Duration of Response (DOR) was investigator-assessed according to RECIST v1.1.


## Acknowledgements

- We thank patients and their families/caregivers, participating study staff, and investigators in this trial.
- This study was sponsored by Celcuity Inc.

## Disclosures

HR declares consultancy/advisory roles with Samsung, Puma, NAPO and Blueprint; institutional research funding from Pfizer, Novartis, Eli Lilly, Genentech/Roche, Macrogenics, OBI, Merck, Immunomedics/Gilead Sciences, Daiichi Sankyo, Seattle Genetics, Eisai, Sermonix, AstraZeneca, Ayala and Astellas.


Figure 2: Treatment-Naïve (1L) Patients’ Best Response (Maximum Percent Change in Sum of Target Lesion Diameters from Baseline; n = 33, Measurable Disease Population)



6 patients had 100% reduction in sum of target lesion diameters; 1 patient had CR, 5 patients had PR due to the presence of non-target lesions.

Note: The dose escalation portion of the study allowed patients with bone-only disease, while the dose expansion portion required subjects to have measurable disease. This figure represents maximum changes in sum of target lesions diameters from baseline in patients with measurable disease only: seven from Dose Escalation Arm A and 26 from Dose Expansion Arm A.

Figure 3: Progression-Free Survival for Treatment-Naïve Patients (n = 41, Full Analysis Set)



Subjects at Risk:

Total 41 34 29 28 23 21 19 18 18 17 17 14 13 12 12 11 9 6 2 1 1 1 0

Note: PFS was investigator-assessed according to RECIST v1.1.

## CONCLUSIONS

- Gedatolisib in combination with letrozole and palbociclib demonstrated encouraging efficacy and durable responses in the subgroup of treatment-naïve patients with ER+/HER2- advanced breast cancer.
- Promising efficacy results, with a median PFS of 48.6 months and ORR of 79%, in patients with measurable and evaluable disease, was very encouraging and compares favorably to published data with other therapies in this setting.
- The study regimen was well tolerated, with < 10% (4/41) patients discontinuing due to treatment-related adverse events.
- A Phase 3 study evaluating gedatolisib (3 weeks on/1 week off) with palbociclib and fulvestrant in HR+/HER2- ABC is currently enrolling.
- These preliminary results are very encouraging and warrant further evaluation of gedatolisib in treatment-naïve ER+/HER2- ABC.

## References

1. Turner NC, et al. (2015) doi: 10.1056/NEJMoa1505270.
2. Andre F, et al. (2019) doi: 10.1056/NEJMoa1813904.
3. Rugo HS, et al. (2020) doi: 10.1200/JCO.2020.38.15\_suppl.1006.
4. Baselga J, et al. (2012) doi: 10.1056/NEJMoa1109653.
5. Dhakal A, et al. (2020) doi: 10.1177/1178223420944864.
6. Forero-Torres A, et al. (2018) *J Clin Oncol*. 36(15\_suppl): 1040-1040.
7. Layman RM, et al. (2021) SABCS 2021 Dec 7–10; San Antonio, TX. Abstract 1017.